Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
D000818:Animals; D002230:Carbidopa / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004221:Disulfiram / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D008750:Methyldopa / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D051379:Mice; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy; D010643:Phenoxybenzamine / Q000494:pharmacology; D010868:Pimozide / Q000494:pharmacology; D012110:Reserpine
D010643:Phenoxybenzamine; D010868:Pimozide; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D002230:Carbidopa; D004221:Disulfiram; D002746:Chlorpromazine